Topics for the NCT Trial Center´s newsletter in November 2016 are the clinical trials:

• CTLA-4 NY-ESO-1, a phase II trial of ipilimumab in patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1
• IVAC-ALL, a prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF in children with relapsed acute lymphoblastic leukemia
• Vorinostat, a phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia

Please follow the links for an English or a German version of the newsletter.